NewAmsterdam Pharma Company N.V. (NAMS) reported Q1 Revenue
Tweet
Share
E-mailGet Alerts NAMS Hot Sheet
Join SI Premium – FREE
NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS) reported Q1 Revenue for the quarter came in at $3.04 million versus the consensus estimate of $1.18 million.
For earnings history and earnings-related data on NewAmsterdam Pharma Company N.V. (NAMS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blue Owl leads $2.4 billion debt deal for Iren data center
- IP Strategy Holdings receives Nasdaq noncompliance notice over late 10-Q
- Hafnia Limited (HAFN) Tops Q2 EPS by 1c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
